Hydroxychloroquine Market has the potential to be a huge game changer in medical history
In 2019, the global hydroxychloroquine market was worth $1.9 billion, and by 2027, it is expected to be worth $4.6 billion. From 2020 to 2027, the market is expected to develop at a 7.9% compound annual growth rate (CAGR).
When paired with chloroquine, hydroxychloroquine, an anti-malarial medication, has the potential to be a huge game-changer in medical history. It showed antiviral effectiveness against (SARS-CoV-2) severe acute respiratory syndrome-coronavirus-2 in a few small, experimental, uncontrolled or poorly controlled clinical investigations. Hypotheses are formed as a result of such investigations. However, following President Trump's tweet, the market's situation suddenly shifted, with reports of drug shortages in pharmacies within 24 hours. In the midst of the outbreak, some countries, including the United States and India, are approving its usage as a COVID-19 prevention tool.
The surge in demand for the treatment has fueled the expansion of the worldwide hydroxychloroquine market, prompting the Indian government to increase production of the drug. IPCA Laboratories, which controls almost 70% of the market in this area in India, has tenfold boosted production.
The nationwide lockout, on the other hand, hampered worldwide market expansion. In addition, logistical disruptions and a scarcity of raw materials, which are largely sourced from China, have stifled market expansion. With the resumption of normal operations in China following the lockdown, and the backward integration of some industry participants, the market has been able to cope to a certain extent.
IPCA Laboratories agreed to buy Maharashtra-based Ramdev Chemical Pvt. Ltd. in April 2019. IPCA Laboratories is supposed to buy the company, which is involved in the marketing and production of sophisticated medication intermediates, active pharmaceutical ingredients (APIs), bespoke synthesis compounds, and fine chemicals, according to the contract.As a result, IPCA Laboratories' initiative will assist the company in growing medicine production capacity and contributing to satisfying current demand.
The Indian government banned the drug's export on March 25, 2020, to ensure that the country has enough medication to meet domestic demands. However, the government later decided to partially lift the restriction. The SAARC members, along with another 30 nations, the United States, and West Asia, proposed that India lift the export ban. Because of the increasing demand for the drug, pharmaceutical companies in the country want to boost output by 5 to 6 times to over 70 metric tonnes by May 2020. Aside from IPCA Laboratories Ltd., Zydus Cadila and Wallace Pharmaceuticals are two additional major hydroxychloroquine producers.
Product type, distribution channel, disease, and geography are all segments of the worldwide hydroxychloroquine market. The market is divided into tablet and active pharmaceutical ingredients segments based on product type. The market is segmented into hospital pharmacy, internet pharmacy, specialty drug store, and retail pharmacy, depending on the distribution channel. Malaria, rheumatoid arthritis, lupus erythematosus, coronavirus, and other disorders are among those studied. The hydroxychloroquine market is studied in North America, Europe, Asia-Pacific, and Latin America and the Caribbean (Latin America, Middle East, and Africa).
Key Benefits
Comments
Post a Comment